Trial Profile
A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor (NERI), in the treatment of major depression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Edivoxetine (Primary) ; Escitalopram
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 24 Apr 2008 Actual number patients enrolled was 470.
- 24 Apr 2008 Actual completion date for this trial is 1 March 2008.
- 24 Apr 2008 Status changed from in progress to completed.